Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for deucravacitinib (sotyktu)

  1. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    28 June 2023
    View recommendations

    Sections for TA907